UBS Group’s Opexa Therapeutics, Inc. OPXAW Stock Holding History

UBS Group’s Portfolio OPXAW Stock Details OPXAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-95	Closed	–	–	8303
2017 Q1	$0	Buy	+95	New	+$2	﹤0.01%	8309
2016 Q4	–	Sell	-7,161	Closed	-$1K	–	8312
2016 Q3	$1K	Buy	7,161 +6,757	+1,673%	+$619	﹤0.01%	7584
2016 Q2	$0	Sell	404 -3,661	-90%	-$242	﹤0.01%	8199
2016 Q1	$0	Sell	4,065 -6,575	-62%	-$466	﹤0.01%	8581
2015 Q4	$1K	Buy	10,640 +2,388	+29%	+$263	﹤0.01%	8226
2015 Q3	$1K	Hold	8,252	–	–	﹤0.01%	8296
2015 Q2	$1K	Buy	+8,252	New	+$1.23K	﹤0.01%	8378

Other funds holding OPXAW

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

UBS Group's OPXAW Position: Q2 2017 in Review

UBS Group sold out of Opexa Therapeutics, Inc. (OPXAW) in Q2 2017, closing a stake of 95 shares.

UBS Group first reported a position in OPXAW in Q2 2015 and held it in 7 quarters. The position peaked at $1K in Q3 2016. 4 funds tracked by Wall St. Rank hold OPXAW as of Q2 2017.

UBS Group reported no remaining Opexa Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
UBS Group sold 95 Opexa Therapeutics, Inc. shares in Q2 2017.
UBS Group first reported a position in Opexa Therapeutics, Inc. in Q2 2015 and held it in 7 quarters.
UBS Group's Opexa Therapeutics, Inc. position peaked at $1K in Q3 2016.
4 funds tracked by Wall St. Rank held Opexa Therapeutics, Inc. as of Q2 2017.

Based on UBS Group's 13F filing for Q2 2017, filed 14 Aug 2017.